Drugs / SY-2101
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04996030 | Sep 2021 → Jan 2024 | acute promyelocytic leukemia | Syros Pharmaceuticals | Suspended | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SY-2101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04996030 ↗ |
| Route | Oral | “SY-2101 is an oral formulation of a drug called arsenic trioxide (ATO).” NCT04996030 ↗ |